How often does Entrada Therapeutics move more than the options market prices?

1 of the last 8 reports moved at least as far as the implied move.

TRDANasdaqPharmaceutical Preparations

Entrada Therapeutics, Inc. (TRDA) earnings date, market-implied expected move, and options open interest by expiry

4.53

+0.13 · +2.88%

post 4.53 0.00%

Closed16:00 ET

Open4.49Volume317,344Mkt cap$176.6MEPS-3.97

Day4.27 – 4.53100%52-wk4.11 – 16.453%

TRDA

Entrada Therapeutics, Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

Next report

Nov 5

before open · in 5 days

est.Q3 FY26

Calendar

Next report

Last report

−2.49%

vs ±56.7% implied · ×0.04

shaded = implied · ▲▼ = realized

Aug 5 '26 · confirmed

Implied vs realized

Linked news

8dVRTX · customerPhase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

News

Largest filed tie

13F top-10 QoQ

−0.86%

shares held · 10 largest managers

13F · Jun 30 '26124d lag

128 managers

Top fund weight

0.01%

TRDA weight · IWM

N-PORTJun 30 '26

3 funds

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Entrada Therapeutics (TRDA) is expected to report on Nov 5 before open (estimated date).

Implied vs realized

8 reports

1 of 8≥ implied

avg implied: ±48.7%
avg realized: ±9.6%

Feb 27 '25Feb 27 '25confirmed±31.7%▼−0.33%×0.01

May 8 '25May 8 '25confirmed±53.3%▲+5.64%×0.11

Aug 6 '25Aug 6 '25confirmed±81.8%▲+2.06%×0.03

Q3 FY25Nov 6 '25confirmed±61.5%▲+0.14%×0.00

Jan 8 '26Jan 8 '26confirmed±42.8%▼−2.14%×0.05

Q1 FY26Feb 26 '26confirmed±38.0%▲+6.76%×0.18

May 7 '26May 7 '26confirmed±24.3%▼−57.27%×2.36

Q2 FY26Aug 5 '26confirmed±56.7%▼−2.49%×0.04

quarterimplied−85%0+85%realized×

Q2 FY26±56.7%▼−2.49%×0.04

May '26±24.3%▼−57.27%×2.36

Q1 FY26±38.0%▲+6.76%×0.18

Jan '26±42.8%▼−2.14%×0.05

Q3 FY25±61.5%▲+0.14%×0.00

Aug '25±81.8%▲+2.06%×0.03

2 older reports

May '25±53.3%▲+5.64%×0.11

Feb '25±31.7%▼−0.33%×0.01

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

OI · 1 expiry · Oct 27 close

0.01OI · 1 expiry · Oct 27 closeP/C open interest · Dec 18 · first expiry after the report

PUTS · chgexpiry · days · P/CCALLS · chgP/C

610%Dec 1848d5,1520%

ExpiryPutsCallsP/C

Dec 1848d610%5,1520%0.01

Hatched = puts · solid = calls · bars scaled per expiry · chg = OI vs prior sessionSource: options EOD

Positioning

Linked exposure

No implied move.

Linked exposure

Revenue flow

as filedQ2 FY26

−4762.03%as filednet margin · revenue +2.63% QoQ · −53.95% YoY

Revenue$898,000+2.63%

Gross profit$898,000100.00%+2.63%

Operating income−$45M−5007.02%−6.29%

Pre-tax income−$43M−7.68%

Net income−$43M−4762.03%−7.67%

Cost of revenue$0—

Operating expenses$46M+6.21%

Tax$35,000−7.89%

Other income$2M−14.82%

Source: SEC filings · standardized · QE Jun 30 '26 · bars = % of revenue

Revenue flow

Intraday

15m bars

Hatch = extended hours · ▯ up · ▮ downSource: market data · 16:00 ET

Intraday

Event sensitivity

PPI ×1.34· ±4.2% vs ±3.1% · 10 releases

eventrelease day|move|up · n×base

PPIproducer prices±4.2%5 of 10×1.34

CPIconsumer prices±4.0%7 of 10×1.28

FOMCrate decision±4.0%12 of 24×1.26

NFPjobs report±3.5%4 of 10×1.12

PCEpersonal income & outlays±3.5%9 of 19×1.12

CPROFcorporate profits±2.9%7 of 12×0.93

GDPgross domestic product±2.9%12 of 19×0.92

Bar = avg |move| to ±5% · tick = ±3.1% avg day · ×base = |move| ÷ ±3.1% · min 6 releases

Earnings history

EPS -1.01 · consensus —

Quarter	Reported	EPS	Consensus
Q2 FY26	Aug 5 '26 · confirmed	-1.01	—
Q1 FY26	Feb 26 '26 · confirmed	-0.95	—
Q3 FY25	Nov 6 '25 · confirmed	-1.06	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod